The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | A Phase I trial combining PF-08046040 (SEA-CD70) with azacitidine to treat MDS
Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, comments on the promising results of a Phase I study combining PF-08046040 (SEA-CD70), a CD70-directed antibody, with azacitidine in patients with myelodysplastic syndromes (MDS). Dr Fathi notes that the combination achieved a significant proportion of marrow responses, including complete remissions, and plans for further expansion and investigation in larger populations of patients are underway. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
So, yes, this was an abstract presentation. I happen to be the senior author on that particular abstract. So this agent that was developed by Seattle Genetics and now is owned by Pfizer is a CD70 antibody. And CD70 is a new and emerging target in acute myeloid leukemia. In combination with azacitidine, it appears to have particular promise. I mentioned acute myeloid leukemia, but I should have said myeloid malignancies because this particular study is for patients who have myelodysplastic syndrome and high-risk myelodysplastic syndrome...
So, yes, this was an abstract presentation. I happen to be the senior author on that particular abstract. So this agent that was developed by Seattle Genetics and now is owned by Pfizer is a CD70 antibody. And CD70 is a new and emerging target in acute myeloid leukemia. In combination with azacitidine, it appears to have particular promise. I mentioned acute myeloid leukemia, but I should have said myeloid malignancies because this particular study is for patients who have myelodysplastic syndrome and high-risk myelodysplastic syndrome. And it’s a combination of azacitidine plus the CD70 antibody. And we found that the data was quite promising. A large proportion of patients in this setting achieved marrow responses, including complete remissions. So we shall see ultimately where this combination goes. I think there is an expansion, a further expansion phase that we are looking into, and then future plans hopefully to further investigate this in larger populations of patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Pfizer: Consultancy; Abbvie: Consultancy, Research Funding; Novartis: Consultancy; Menarini Group: Consultancy; Orum: Consultancy; Agios: Ended employment in the past 24 months; Kite: Consultancy; AstraZeneca: Honoraria; BMS/Celgene: Consultancy; Bristol Myers Squibb: Consultancy, Research Funding; Servier: Consultancy, Research Funding; ImmunoGen: Consultancy; Genentech: Honoraria; Autolus: Consultancy; MorphoSys: Consultancy; Forma: Consultancy; Rigel: Consultancy; Astellas: Consultancy; Mablytics: Consultancy; Ipsen: Consultancy; Gilead: Consultancy; PureTech: Consultancy; Foghorn, Blueprint Medicines, Kura, Trillium: Honoraria; AbbVie, BMS/Celgene, and Agios/Servier: Research Funding; Ispen: Consultancy; Remix: Consultancy; Takeda: Consultancy; Amgen: Consultancy; EnClear: Consultancy; Daiichi Sankyo: Consultancy.
